Sanara MedTech Provides FY26 Revenue Guidance and Reaffirms Strong FY25 Preliminary Results

summarizeSummary

Sanara MedTech Inc. released an investor presentation outlining its strategy and providing revenue guidance of $116 million to $121 million for fiscal year 2026, alongside reaffirming its strong preliminary fiscal year 2025 results.

check_boxKey Events

• FY26 Revenue Guidance Issued

  The company projects net revenue between $116 million and $121 million for fiscal year 2026.

• Continued Growth Anticipated

  This guidance represents a year-over-year increase of approximately 13% to 17%.

• FY25 Preliminary Results Reaffirmed

  The company reiterated its preliminary net revenue for fiscal year 2025 at $102.7 million to $103.2 million, an increase of 19% year-over-year, consistent with the January 23, 2026 disclosure.

• Investor Presentation Filed

  The 8-K includes an investor presentation to be used at the TD Cowen 46th Annual Health Care Conference on March 3, 2026.

auto_awesomeAnalysis

This 8-K, filed in conjunction with an investor presentation for an upcoming conference, provides crucial forward-looking information for Sanara MedTech. While the preliminary FY25 results were previously disclosed on January 23, 2026, the new fiscal year 2026 revenue guidance of $116 million to $121 million (representing 13% to 17% year-over-year growth) offers investors a clear outlook on the company's anticipated performance. This positive guidance, following strong preliminary 2025 results, suggests continued operational momentum and growth in its surgical business. Investors will likely view this as a positive signal for the company's trajectory.